Hodgkin’s Disease and Non-Hodgkin’s Lymphoma.pptVIP

Monoclonal Abs - Rituxan Radioimmunotherapy with Y-90 Zevalin Ibritumomab Murine monoclonal antibody parent of Rituximab Tiuxetan Conjugated to antibody, forming strong urea-type bond Stable retention of Y-90 Y-90 radionuclide Beta radiation Chelator Monoclonal antibody New Treatment Options Velcade + Flavoperidol – MCC Trial Velcade + Darinaparsin Conclusion Discussed Hodgkin’s Disease Discussed Non-Hodgkin’s Lymphoma Discussed Classification Systems Discussed Treatment Options * Now we will turn our attention to the number of new cancers anticipated in the US this year. It is estimated that almost 1.4 million new cases of cancer will be diagnosed in 2006. Cancers of the prostate and breast will be the most frequently diagnosed cancers in men and women, respectively, followed by lung and colorectal cancers both in men and in women. * Lung cancer is, by far, the most common fatal cancer in men (31%), followed by colon rectum (10%), and prostate (9%). In women, lung (26%), breast (15%), and colon rectum (10%) are the leading sites of cancer death. * * * Slide 33: Combination chemotherapy is the standard treatment for most patients with Hodgkin Disease. In the 20 to 30% of patients who fail conventional therapy, autologous transplantation is an effective salvage therapy. A total of 3,526 patients with Hodgkin disease underwent autologous transplantation in 1996-2001 and were registered with the ABMTR. Patients transplanted in first remission had a 3-year survival probability of 82 ± 3%; those transplanted in 3 2nd remission had a probability of 77 ± 2%. Although survival rates are lower, there is still a substantial salvage rate for patients who never achieved remission with conventional therapy (58 ± 2%) and for those transplanted in relapse (65 ± 1%). * Key Point: The REAL/WHO classification system makes it possible to define clinically distinct types of NHL.1,2 This is a clinical evaluation of the REAL classifications in 1403 cases of NHL at 9 st